Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRATA: Natalizumab Safety and Tolerability Extension in MS
NCT00297232Phase 3Terminated
- Sponsor
- Biogen
- Start
- Mar 2006
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Mar 2006; status: terminated.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00297232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297232.